Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), Walgreens Boots Alliance ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

A handful of biotech stocks made an elite list despite being unprofitable. But many show robust sales growth and constructive ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...

In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against other best performing healthcare stocks so far in 2025. Despite the ongoing craze ...

Good morning, and welcome to the Axsome Therapeutics' fourth quarter and full year 2024 conference call. Currently, all participants are in listen-only mode. Later, there will be a question-and ...

Significant R&D investment of $55 million highlights a focus on pipeline development. Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Axsome Therapeutics, a biopharmaceutical company targeting central nervous system (CNS) disorders, develops novel therapies for depression, narcolepsy, and other CNS conditions. Its current ...